Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson’s disease
Abstract Levodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms (NMS). Nevertheless, studies with patient Quality of Life (QoL) as a primary endpoint are scarce. To assess the effect of LCIG on Advanced Parkinson’s Disease (APD) patients QoL. Secondarily...
Guardado en:
Autores principales: | Francesc Valldeoriola, María José Catalán, Francisco Escamilla-Sevilla, Eric Freire, Jesús Olivares, Esther Cubo, Diego Santos García, Matilde Calopa, Pablo Martínez-Martín, Juan Carlos Parra, Gloria Arroyo, José Matías Arbelo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b29e73979abe4d5b826cdca39dd2e61d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Von Economo’s disease and postencephalitic parkinsonism responsive to carbidopa and levodopa
por: Bigman DY, et al.
Publicado: (2018) -
Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
por: Hauser RA, et al.
Publicado: (2018) -
Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
por: David J Brooks
Publicado: (2008) -
Levodopa-Carbidopa Intestinal Gel Infusion Therapy Discontinuation: A Ten-Year Retrospective Analysis of 204 Treated Patients
por: Constantin VA, et al.
Publicado: (2020) -
Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo®)
por: Paolo Solla, et al.
Publicado: (2010)